D-1458-2019 Class II Terminated

Recalled by Macleods Pharma Usa Inc — Plainsboro, NJ

FDA drug recall D-1458-2019 was initiated by Macleods Pharma Usa Inc on Jun 20, 2019 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is terminated (terminated Oct 26, 2021). Affected quantity: 4277 bottles (4,277,000 tablets).

Recall details

Product Type
Drugs
Report Date
Jul 17, 2019
Initiation Date
Jun 20, 2019
Termination Date
Oct 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4277 bottles (4,277,000 tablets)

Product description

Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-045-44

Reason for recall

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Distribution pattern

Nationwide

Code information

BLI710A Nov 2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1458-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1458-2019. Report a data issue: hello@regdatalab.com.